212 related articles for article (PubMed ID: 18780870)
1. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Chlebowski RT; Col N
J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
[No Abstract] [Full Text] [Related]
2. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Gurwitz D; Newman W
J Natl Cancer Inst; 2008 Sep; 100(18):1331; author reply 1332-4. PubMed ID: 18780871
[No Abstract] [Full Text] [Related]
3. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
5. Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Barros-Oliveira MDC; Costa-Silva DR; Andrade DB; Borges US; Tavares CB; Borges RS; Silva JM; Silva BBD
Rev Assoc Med Bras (1992); 2017 Apr; 63(4):371-378. PubMed ID: 28614542
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
7. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Pharoah PD; Abraham J; Caldas C
J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
[No Abstract] [Full Text] [Related]
8. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Nakamura Y; Ratain MJ; Cox NJ; McLeod HL; Kroetz DL; Flockhart DA
J Natl Cancer Inst; 2012 Aug; 104(16):1264; author reply 1266-8. PubMed ID: 22851270
[No Abstract] [Full Text] [Related]
9. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Stanton V
J Natl Cancer Inst; 2012 Aug; 104(16):1265-6; author reply 1266-8. PubMed ID: 22851267
[No Abstract] [Full Text] [Related]
10. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Vakaet L
J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
[No Abstract] [Full Text] [Related]
11. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
12. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Kelly CM; Pritchard KI
J Natl Cancer Inst; 2012 Mar; 104(6):427-8. PubMed ID: 22395645
[No Abstract] [Full Text] [Related]
13. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM
Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
[TBL] [Abstract][Full Text] [Related]
14. Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Berruti A; Tucci M; Mosca A; Vana F; Ardine M; Dogliotti L; Angeli A; Bertoldo F
J Clin Oncol; 2007 Apr; 25(11):1455-6. PubMed ID: 17416873
[No Abstract] [Full Text] [Related]
15. Extended adjuvant therapy for breast cancer--how much is enough?
Prowell TM; Stearns V
J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
[No Abstract] [Full Text] [Related]
16. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Cianfrocca M; Wolff AC
Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
[TBL] [Abstract][Full Text] [Related]
17. Targeting breast cancer with hormonal treatment options.
Mellington TE; Fields MM
Nurse Pract; 2008 May; 33(5):17-22; quiz 22-3. PubMed ID: 18458623
[No Abstract] [Full Text] [Related]
18. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
19. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Nabholtz JM
Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]